Company Metrics

• 0 P/E
• 0 P/S
• 5.64 P/B
• -0.3 EPS
• 34,980.82% Cash ROIC
• 3.45 Cash Ratio
• 0 / 0% Dividend
• 1.57M Avg. Vol.
• 60.14M Shares
• 123.4M Market Cap.

Company Description

Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of various human diseases. The company's compounds target various prevalent medical conditions, primarily rheumatoid arthritis, psoriasis, cancer, other immunological disorders, and neurogenic orthostatic hypotension associated with Parkinson's disease and other autonomic disorders. It offers Droxidopa, an orally active synthetic precursor of norepinephrine for the treatment of symptomatic neurogenic orthostatic hypotension, freezing gait in Parkinson's disease, and intradialytic hypotension in Japan. The company develops droxidopa in three indications, such as neurogenic orthostatic hypotension, intradialytic hypotension, and fibromyalgia. It also develops a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases, such as a portfolio of metabolically inert antifolate molecules, including CH-1504 for the treatment of rheumatoid arthritis that is in a phase II head-to-head clinical trial; and CH-4051, which completed the phase I study designed to determine the maximum tolerated dose based on results of single-ascending and multiple-ascending dose evaluations. In addition, the company develops antifolate program, a platform consisting of a portfolio of dihydroorotate dehydrogenase(DHODH), inhibiting compounds known as the I-3D portfolio, a group of orally active compounds that inhibit the enzyme DHODH for the treatment of autoimmune diseases and transplant rejection. Chelsea Therapeutics International, Ltd. was founded in 2002 and is headquartered in Charlotte, North Carolina.
less

Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of various human diseases. The company's compounds target various prevalent medical conditions, primarily rheumatoid arthritis, psoriasis, cancer, other immunological disorders, and neurogenic orthostatic h...
more

News